FTC Staffing Up For More Biopharma Merger Oversight
The Federal Trade Commission plans to bolster its oversight of biopharma mergers by adding staff to "specialize" in the "increasingly complex" actions in this sector, according to the agency's budget request for fiscal year 2011
You may also be interested in...
In the swirling alliances of the health care reform debate, a press conference by FTC and House Democrats features a consumer who feels he was harmed by the deal between Solvay and generic firms.
Julie Brill, as Vermont's Assistant Attorney General, headed state efforts to have drug companies disclose payments to physicians and to restrict use of data on physician prescribing habits for marketing.
The FTC requires Pfizer to divest half of Wyeth's animal health business but finds their human drug products, particularly for Alzheimer's disease and osteoporosis, do not compete with each other.